Beta-2 microglobulin (B2M) mRNA (B2M mRNA)

Beta-2 microglobulin (B2M) mRNA is the genetic template for the B2M protein, which serves as an obligatory light chain for the assembly and stable surface expression of all Major Histocompatibility Complex (MHC) class I molecules (UniProt P61769). These MHC class I complexes are vital for the presentation of endogenous antigens to CD8+ cytotoxic T lymphocytes, playing a central role in immune recognition (NCBI Gene 567). Targeting B2M mRNA via short hairpin RNA (shRNA) is a therapeutic strategy designed to induce RNA interference (RNAi), leading to the degradation of the transcript and a subsequent reduction in B2M protein levels (PubMed: 30635460). This approach is frequently utilized in the development of allogeneic, or "off-the-shelf," cellular therapies, such as CAR-T cells, to minimize the risk of graft rejection by the recipient's immune system (PubMed: 28923816). By reducing MHC class I expression, the engineered cells can evade detection by host T cells, thereby potentially enhancing their persistence and therapeutic window in the patient. However, the complete absence of MHC class I can trigger "missing self" recognition by Natural Killer (NK) cells, which may limit the survival of the therapeutic cells. Monitoring B2M levels serves as a critical biomarker for assessing the efficiency of the knockdown and the potential immunogenicity of the engineered product.

Other names

B2M transcriptBeta-2-microglobulin messenger RNAB2M messenger RNA

RNA interference-mediated degradation of B2M mRNA leading to reduced surface expression of MHC class I molecules